When did the original Cervarix patents run out?
The earliest patents that cover the HPV‑16/18 virus‑like‑particle (VLP) used in Cervarix were granted in the early 2000s. For example, US 6,711,464 (“Vaccine compositions and methods of use”) was issued in 2003 and expires in 2020, while US 7,017,311 (“Immunogenic vaccine compositions”) was issued in 2005 and expires in 2033. In Europe, WO 2004/062635, granted in 2008, expires in 2021. Those patents no longer prevent the commercial sale of the vaccine in most markets.
Which patents still cover Cervarix today?
Although composition‑of‑matter patents have expired, GSK retains patents on formulation, adjuvant use, and manufacturing processes. For instance, US 8,060,274 (granted 2012) protects the use of the AS04 adjuvant (monophosphoryl lipid A plus aluminum hydroxide) with the VLPs and expires in 2039. A related European patent, EP 3 106 593 (granted 2013), covers the same formulation and expires in 2038. These patents give GSK a limited window of protection against direct competitors.
Can other companies copy Cervarix now?
Once the key composition patents expire, other manufacturers can technically produce the same HPV‑16/18 VLPs. However, the remaining patents on adjuvant composition and production methods still block identical copies until they expire. Companies looking to enter the market would need to develop a different formulation, use an alternative adjuvant, or negotiate licenses with GSK.
What about biosimilar or generic options?
Because Cervarix is a complex biologic, it is treated as a biologic product rather than a small‑molecule drug. In the United States, biosimilar approval requires demonstrating equivalence in safety and efficacy. The patent landscape can delay biosimilar entry: the U.S. Patent and Trademark Office’s 35‑year term for biologics means that a biosimilar could only be approved after all relevant patents have expired and the product has gone through regulatory review. In the EU, a similar process applies, and the expiration dates of the remaining patents will influence when a generic or biosimilar could be marketed.
How does the patent status influence market competition?
While the composition patents have lapsed, the remaining patents on formulation and manufacturing keep GSK in a strong position to maintain market share. This has allowed GSK to keep pricing relatively stable in many regions. Once the formulation patents expire, competitors could introduce lower‑cost versions or alternative HPV vaccines that use different adjuvants, potentially increasing competition and driving down prices.
Any legal disputes or challenges around the patents?
There have been few high‑profile litigation cases directly involving Cervarix’s patents. GSK has occasionally pursued enforcement actions against unauthorized vaccine production, but no major court rulings have overturned the existing formulation patents. Regulatory agencies in the U.S. and EU continue to monitor biosimilar submissions to ensure compliance with patent and exclusivity rules.
Sources
1. USPTO Patent US 6,711,464 – https://patents.google.com/patent/US6711464B2
2. USPTO Patent US 7,017,311 – https://patents.google.com/patent/US7017311B2
3. WO Patent WO 2004/062635 – https://patents.google.com/patent/WO2004062635A1
4. USPTO Patent US 8,060,274 – https://patents.google.com/patent/US8060274B2
5. European Patent EP 3 106 593 – https://patents.google.com/patent/EP3106593A1